MENLO
PARK, Calif., Nov. 4, 2024
/PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company
whose mission is to detect cancer early when it can be cured, today
announced that company management will present at the Canaccord
Genuity MedTech, Diagnostics and Digital Health & Services
Forum in New York on Thursday, Nov. 21 at 11:00
a.m. ET.
Live and replay webcasts may be accessed in the investor
relations section of GRAIL's website at investors.grail.com. The
webcast will be archived and available for reply for at least 30
days after the event.
About GRAIL
GRAIL is a healthcare company whose
mission is to detect cancer early, when it can be cured. GRAIL is
focused on alleviating the global burden of cancer by using the
power of next-generation sequencing, population-scale clinical
studies, and state-of-the-art machine learning, software, and
automation to detect and identify multiple deadly cancer types in
earlier stages. GRAIL's targeted methylation-based platform can
support the continuum of care for screening and precision oncology,
including multi-cancer early detection in symptomatic patients,
risk stratification, minimal residual disease detection, biomarker
subtyping, treatment and recurrence monitoring. GRAIL is
headquartered in Menlo Park, CA
with locations in Washington,
D.C., North Carolina, and
the United Kingdom.
For more information, visit grail.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302295742.html
SOURCE GRAIL, Inc.